Literature DB >> 11036202

Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons.

J Ahluwalia1, L Urban, M Capogna, S Bevan, I Nagy.   

Abstract

Expression of cannabinoid 1 (CB1) and vanilloid 1 (VR1) receptor proteins was studied in adult, cultured rat dorsal root ganglion neurons. Immunostaining of CB1 receptors alone produced labelling in 57+/-2% of the cultured dorsal root ganglion neurons (n=3 cultures). The area of the labelled cells was between 200 and 800 microm(2) with an average of 527+/-68 microm(2). VR1 immunolabelling revealed immunopositivity in 42+/-6% of the total population of dorsal root ganglion neurons. Cells showing VR1-like immunopositivity had an area between 200 and 600 microm(2). The mean area of the VR1-like immunopositive neurons was 376+/-61 microm(2). Double immunostaining with antisera raised against the CB1 and VR1 receptor proteins, showed a high degree of co-expression between CB1 and VR1 receptors. An average of 82+/-3% of the CB1-like immunopositive cells also showed VR1-like immunoreactivity (n=3 cultures) while 98+/-2% of the VR1-like immunolabelled neurons showed CB1 receptor-like immunostaining (n=3 cultures). Our data suggests that nociceptive primary sensory neurons co-express CB1 and VR1 receptors to a very high degree. We propose that this may provide an anatomical basis for a powerful combination of VR1 mediated excitation and CB1-mediated inhibition of nociceptive responses at central and peripheral terminals of nociceptive primary afferents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036202     DOI: 10.1016/s0306-4522(00)00389-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  82 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons.

Authors:  Gabor Veress; Zoltan Meszar; Dora Muszil; Antonio Avelino; Klara Matesz; Ken Mackie; Istvan Nagy
Journal:  Brain Struct Funct       Date:  2012-05-22       Impact factor: 3.270

Review 3.  Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics.

Authors:  J Sousa-Valente; A P Andreou; L Urban; I Nagy
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

4.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

Review 5.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 6.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

7.  Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus.

Authors:  Natalia Dmitrieva; Karen J Berkley
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.

Authors:  T J Price; G Helesic; D Parghi; K M Hargreaves; C M Flores
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.

Authors:  Beatriz Fioravanti; Milena De Felice; Cheryl L Stucky; Karen A Medler; Miaw-Chyi Luo; Luis R Gardell; Mohab Ibrahim; T Phil Malan; Henry I Yamamura; Michael H Ossipov; Tamara King; Josephine Lai; Frank Porreca; Todd W Vanderah
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 10.  An overview on the biochemistry of the cannabinoid system.

Authors:  María Gómez-Ruiz; Mariluz Hernández; Rosario de Miguel; Jose A Ramos
Journal:  Mol Neurobiol       Date:  2007-06-30       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.